Acadia Pharmaceuticals Inc (NASDAQ:ACAD) Institutional Investor Positioning Change

Sentiment for Acadia Pharmaceuticals Inc (NASDAQ:ACAD)

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) institutional sentiment increased to 1.22 in 2018 Q2. Its up 0.33, from 0.89 in 2018Q1. The ratio is better, as 90 hedge funds started new and increased stock positions, while 74 sold and reduced stock positions in Acadia Pharmaceuticals Inc. The hedge funds in our partner’s database now hold: 114.30 million shares, down from 119.37 million shares in 2018Q1. Also, the number of hedge funds holding Acadia Pharmaceuticals Inc in their top 10 stock positions increased from 1 to 2 for an increase of 1. Sold All: 31 Reduced: 43 Increased: 55 New Position: 35.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $2.79 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of ParkinsonÂ’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of AlzheimerÂ’s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

The stock increased 3.03% or $0.57 during the last trading session, reaching $19.39. About 253,088 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 62.95% since December 6, 2017 and is downtrending. It has underperformed by 78.57% the S&P500.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on February, 26. They expect $-0.56 EPS, down 1.82 % or $0.01 from last year’s $-0.55 per share. After $-0.50 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 12.00 % negative EPS growth.

Great Point Partners Llc holds 4.23% of its portfolio in ACADIA Pharmaceuticals Inc. for 2.00 million shares. Baker Bros. Advisors Lp owns 27.23 million shares or 3.12% of their US portfolio. Moreover, Ghost Tree Capital Llc has 2.4% invested in the company for 535,000 shares. The Washington-based First Washington Corp has invested 2% in the stock. Emory University, a Georgia-based fund reported 144,125 shares.

Since January 1, 0001, it had 1 insider purchase, and 0 insider sales for $22.65 million activity.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Ratings analysis reveals 57% of ACADIA Pharmaceuticals’s analysts are positive. Out of 7 Wall Street analysts rating ACADIA Pharmaceuticals, 4 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $17 while the high is $39. The stock’s average target of $26.29 is 35.59% above today’s ($19.39) share price. ACAD was included in 10 notes of analysts from August 6, 2018. The firm earned “Overweight” rating on Friday, September 21 by PiperJaffray. The rating was maintained by Bank of America with “Buy” on Wednesday, October 10. The rating was maintained by Cantor Fitzgerald with “Overweight” on Tuesday, October 16. As per Thursday, November 1, the company rating was maintained by Cantor Fitzgerald. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Market Outperform” rating given on Thursday, August 9 by JMP Securities. PiperJaffray downgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Monday, August 6 to “Neutral” rating.

More notable recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: which released: “Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings? – Nasdaq” on July 31, 2018, also with their article: “7 Stocks To Watch For November 27, 2018 – Benzinga” published on November 27, 2018, published: “40 Biggest Movers From Yesterday – Benzinga” on November 29, 2018. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were released by: and their article: “Interesting ACAD Put And Call Options For November 9th – Nasdaq” published on September 27, 2018 as well as‘s news article titled: “ACADIA Pharmaceuticals Prices Public Offering of Common Stock – Business Wire” with publication date: November 28, 2018.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.